Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination ...

AstraZeneca said a late ... this aggressive form of breast cancer where patients are in urgent need of new treatments," said Peter Schmid, the trial's main investigator. However, the company ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...

Separately, China approved AstraZeneca's Imfinzi (durvalumab) for the 1st-line treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy ...

(Reuters) -AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

June 18 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to ...